Multiple drugs

Multiple drugs Reactions 1704, p259 - 2 Jun 2018 Stem cell mobilization failure : case report A 14-year-old girl experienced stem cell mobilization failure following treatment with vincristine, ifosfamide, doxorubicin, etoposide, cyclophosphamide, temozolomide, irinotecan and bevacizumab [time to reaction onset not stated]. The girl, who was diagnosed with extraosseus stage I Ewing’s sarcoma in April 2009, started receiving treatment with IV vincristine 1.5 mg/m on day 1, IV ifosfamide 2 2 3,000 mg/m on days 1–3, IV doxorubicin 20 mg/m on days 1–3, IV etoposide 150 mg/m on days 1–3 (every three weeks x 6 cycles). She completed 6 cycles prior to surgical resection. In October 2009, she received 8 cycles of consolidation with vincristine IV 1.5 mg/m2 on day 1, IV actinomycin (unspecified) 0.75 mg/m on days 1–2 and IV cyclophosphamide 1,500 mg/m on day 1 (every three weeks x 8 cycles). In April 2010, she developed early relapse and a second chemotherapy line was given with 5 cycles of oral temozolomide 100 mg/m on days 1–21, IV irinotecan 20 mg/m on days 1–5 and 8–13 and IV bevacizumab 350 mg/m on day 1 (every 21 days x 5 cycles). In July 2010, a second surgical resection plus radiotherapy localized in left humeral bone was performed. Due to this chemotherapeutic treatment, she developed stem cell mobilization failure. In response to this, she received first mobilisation regimen included granulocyte colony-stimulating factor (G-CSF). A second mobilisation with chemotherapy followed by G-CSF. However, both the therapies led to insufficient count of CD34+ cell (3/µL) in peripheral blood. Later, she received single compassionate dose of plerixafor, with the CD34+ cell count being 24.5/µL. Total of 1.38 x 10e6 CD34+ cells/kg were collected in a single apheresis processing 5 blood volumes. Autologous stem cell transplant was performed. Author comment: "The number of chemotherapy courses and pretreatment with alkylating agents and platinum compounds. . . are associated with [stem cell mobilization] failure." Vives S, et al. Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing’s sarcoma. Journal of Clinical Apheresis 27: 260-262, No. 5, Nov 2018. Available from: URL: https:// doi.org/10.1002/jca.21234 - Spain 803323920 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Multiple drugs

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/multiple-drugs-COo0eVZvA0
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46902-6
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p259 - 2 Jun 2018 Stem cell mobilization failure : case report A 14-year-old girl experienced stem cell mobilization failure following treatment with vincristine, ifosfamide, doxorubicin, etoposide, cyclophosphamide, temozolomide, irinotecan and bevacizumab [time to reaction onset not stated]. The girl, who was diagnosed with extraosseus stage I Ewing’s sarcoma in April 2009, started receiving treatment with IV vincristine 1.5 mg/m on day 1, IV ifosfamide 2 2 3,000 mg/m on days 1–3, IV doxorubicin 20 mg/m on days 1–3, IV etoposide 150 mg/m on days 1–3 (every three weeks x 6 cycles). She completed 6 cycles prior to surgical resection. In October 2009, she received 8 cycles of consolidation with vincristine IV 1.5 mg/m2 on day 1, IV actinomycin (unspecified) 0.75 mg/m on days 1–2 and IV cyclophosphamide 1,500 mg/m on day 1 (every three weeks x 8 cycles). In April 2010, she developed early relapse and a second chemotherapy line was given with 5 cycles of oral temozolomide 100 mg/m on days 1–21, IV irinotecan 20 mg/m on days 1–5 and 8–13 and IV bevacizumab 350 mg/m on day 1 (every 21 days x 5 cycles). In July 2010, a second surgical resection plus radiotherapy localized in left humeral bone was performed. Due to this chemotherapeutic treatment, she developed stem cell mobilization failure. In response to this, she received first mobilisation regimen included granulocyte colony-stimulating factor (G-CSF). A second mobilisation with chemotherapy followed by G-CSF. However, both the therapies led to insufficient count of CD34+ cell (3/µL) in peripheral blood. Later, she received single compassionate dose of plerixafor, with the CD34+ cell count being 24.5/µL. Total of 1.38 x 10e6 CD34+ cells/kg were collected in a single apheresis processing 5 blood volumes. Autologous stem cell transplant was performed. Author comment: "The number of chemotherapy courses and pretreatment with alkylating agents and platinum compounds. . . are associated with [stem cell mobilization] failure." Vives S, et al. Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing’s sarcoma. Journal of Clinical Apheresis 27: 260-262, No. 5, Nov 2018. Available from: URL: https:// doi.org/10.1002/jca.21234 - Spain 803323920 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off